CRISPR Therapeutics

Vision

Transforming the lives of patients with serious diseases.

Approach

CRISPR Therapeutics aims to develop transformative gene-based medicines based on CRISPR/Cas9 gene editing. For genetically-defined diseases, they can use a guide RNA that directs Cas9 to cut DNA at a specific site in a disease-causing gene, or at a different site, such as a region that regulates genes, to ameliorate the genetic defect through gene disruption or correction. For cell therapies, they can target genes that when disrupted may improve the safety or efficacy of the therapy, or precisely insert new genes to give the cells new abilities.

CRISPR (CRSP) went public in October 2016.